Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03878849 · ClinicalTrials.gov registry record · Phase 2
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
A Phase 2 study of Advanced Ovarian Cancer, sponsored by Allarity Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT03878849 is a Phase 2 study of Advanced Ovarian Cancer that is actively recruiting participants, run by Allarity Therapeutics. The registered enrollment target is 40 participants, below the 697-participant average among 3 other Advanced Ovarian Cancer trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03878849, a Phase 2 study of Advanced Ovarian Cancer, is actively recruiting participants, sponsored by Allarity Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the optimal dose of 2X-121 as single agent therapy at 600 mg daily (split BID 200 mg morning + 400 mg evening) compared to 800 mg daily (split BID 400 mg morning + 400 mg evening) in recurrent, advanced ovarian cancer patients that have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible. The optimal dose will be selected based on an integrated analysis of PK/PD, safety, and efficacy data.
Conditions Studied
Interventions
- DRUG 2X-121
Study Locations (2)
Oklahoma
- OU Health Stephenson Cancer - Oklahoma City
Washington
- Swedish Center for Research and Innovation - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03878849
The ClinicalTrials.gov registry entry for NCT03878849 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 697-participant average among 3 other Advanced Ovarian Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Allarity Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which 2X-121 is the first listed.
NCT03878849 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Oklahoma, Washington.
Frequently Asked Questions
What is clinical trial NCT03878849 about?
NCT03878849 is a clinical study titled "Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer". The purpose of this study is to evaluate the optimal dose of 2X-121 as single agent therapy at 600 mg daily (split BID 200 mg morning + 400 mg evening) compared to 800 mg daily (split BID 400 mg morning + 400 mg evening) in recurrent, advanced ovarian cancer patients that have platinum-resistant dis...
What is the current status of trial NCT03878849?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2019-04-15. Estimated completion is 2027-09.
What conditions does trial NCT03878849 study?
This clinical trial studies the following conditions: Advanced Ovarian Cancer.
What interventions are being tested in trial NCT03878849?
The interventions under investigation include: 2X-121 (DRUG).
Who is sponsoring clinical trial NCT03878849?
This trial is sponsored by Allarity Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03878849 being conducted?
This trial has 2 study locations across Oklahoma, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
RECRUITING · Phase 1
-
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
ACTIVE NOT RECRUITING · Phase 3
-
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.